Bevacizumab-awwb (Mvasi)
Note: this is the first FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Anaplastic glioma
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Colon cancer
- Esophageal cancer
- Follicular lymphoma
- Glioblastoma
- Hepatocellular carcinoma
- Melanoma
- Mesothelioma
- Neuroendocrine tumors
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic NET
- Renal cell carcinoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
- Uterine cancer
- Vascular sarcoma
History of changes in FDA indication
- 9/14/2017: FDA approved for the treatment of patients with the following cancers:
- Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.
- Mvasi is not indicated for the adjuvant treatment of surgically resected colorectal cancer.
- Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line bevacizumab product-containing regimen.
- Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
- Glioblastoma with progressive disease following prior therapy, based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with bevacizumab products.
- Metastatic renal cell carcinoma, in combination with interferon alfa.
- Cervical cancer that is persistent, recurrent, or metastatic disease, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
- Note: Bevacizumab (Avastin) has a label for ovarian cancer, which was not included in the initial FDA approval for bevacizumab-awwb.
Also known as
- Brand name: Mvasi
- Drugs
- Intravenous medications
- Neutral chemotherapy
- Antibody medications
- Anti-VEGFR antibodies
- VEGFR inhibitors
- Adenocarcinoma of unknown primary medications
- Anaplastic glioma medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colon cancer medications
- Esophageal cancer medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hepatocellular carcinoma medications
- Melanoma medications
- Mesothelioma medications
- Neuroendocrine tumor medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Uterine cancer medications
- Vascular sarcoma medications
- FDA approved in 2017
- Biosimilars